Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Rituximab vs Radiation in Ocular Adnexal MALT Lymphoma
NCT06064344Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of rituximab (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Cumulative occurrence rate of complications of grade ≥2 at 2 years. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
rituximab
Beyond the preview
Go deeper on NCT06064344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064344.